

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

YPOZANE 1.875 mg tablets for dogs  
YPOZANE 3.75 mg tablets for dogs  
YPOZANE 7.5 mg tablets for dogs  
YPOZANE 15 mg tablets for dogs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substance:

Each tablet contains 1.875 mg, 3.75 mg, 7.5 mg or 15 mg osaterone acetate.

### Excipients:

Qualitative composition of excipients and other constituents
Lactose monohydrate
Pregelatinised starch
Carmellose calcium
Maize starch
Talc
Magnesium stearate

Round, white, biconvex tablet of 5.5 mm, 7 mm, 9 mm or 12 mm diameter.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs (male).

### 3.2 Indications for use for each target species

Treatment of benign prostatic hypertrophy (BPH) in male dogs.

### 3.3 Contraindications

None.

### 3.4 Special warnings

In dogs with BPH associated with prostatitis, the product can be administered concurrently with antimicrobials.

### 3.5 Special precautions for use

Special precautions for safe use in the target species:

A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. post-operative) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone.

Use with caution in dogs with a history of liver disease, as safety of use of the product in these dogs has not been thoroughly investigated, and as treatment of some dogs with liver disease has resulted in reversible elevation of ALT and ALP in clinical trials.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease in FSH, LH and testosterone, reversible after 16 days. There was no clinical effect.

In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions. Therefore, women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product.

Special precautions for the protection of the environment:

Not applicable.

**3.6 Adverse events**

Dogs (male):

Very common (>1 animal / 10 animals treated):	Increased appetite <sup>1</sup> Hypocortisolaemia <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):	Behavioural disorders (e.g., hyperactivity, decreased activity or more social behaviour) <sup>1</sup>
Uncommon (1 to 10 animals / 1,000 animals treated):	Vomiting and/or diarrhoea <sup>1</sup> Polydipsia <sup>1</sup> , lethargy <sup>1</sup> Polyuria <sup>1</sup> Mammary hyperplasia
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Decreased appetite <sup>1</sup> Galactorrhoea <sup>2</sup> Changes in hair coat (e.g., hair loss or hair modification) <sup>1</sup>

<sup>1</sup> Transient.

<sup>2</sup> Associated with mammary hyperplasia.

In clinical trials, treatment with the veterinary medicinal product was not discontinued and all dogs recovered without any specific therapy.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Not applicable.

### 3.8 Interaction with other medicinal products and other forms of interaction

None known.

### 3.9 Administration routes and dosage

For oral use.

Administer 0.25 – 0.5 mg osaterone acetate per kilogram bodyweight, once a day, for 7 days as follows:

Dog's weight	Strength of tablet to be administered	Number of tablets per day	Treatment duration
3 to 7.5 kg*	1.875 mg tablet	1 tablet	7 days
7.5 to 15 kg	3.75 mg tablet		
15 to 30 kg	7.5 mg tablet		
30 to 60 kg	15 mg tablet		

\*No data are available for dogs less than 3 kg bodyweight

Tablets can be given either directly into the mouth or with food. The maximum dose should not be exceeded.

The onset of clinical response to treatment is usually seen within 2 weeks. The clinical response persists for at least 5 months after treatment.

Re-evaluation by the veterinarian should take place 5 months after treatment or earlier if clinical signs recur. A decision to retreat at this or at a later time point should be based on veterinary examination taking into account the risk benefit profile of the product. If clinical response to treatment is considerably shorter than expected, a re-evaluation of the diagnosis is necessary.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

An overdose study (up to 1.25 mg/kg bodyweight for 10 days, repeated one month later) did not show undesirable effects except for a decrease of cortisol plasma concentration.

### 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

### 3.12 Withdrawal periods

Not applicable.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QG04C X**

### **4.2 Pharmacodynamics**

Benign prostatic hypertrophy (BPH) is a natural consequence of ageing. Over 80% of male dogs above 5 years of age are affected. BPH is a development and enlargement of the prostate due to the male hormone testosterone. This might lead to multiple non-specific clinical signs such as abdominal pain, difficulties in defaecation and urination, blood in urine and locomotive disorders.

Osaterone is a steroid anti-androgen, which inhibits the effects of an excess production of male hormone (testosterone).

Osaterone acetate is a steroid chemically related to progesterone, and as such it has potent progestagen and potent anti-androgen activity. Also, the major metabolite of osaterone acetate (15 $\beta$ -hydroxylated - osaterone acetate) has anti-androgenic activity. Osaterone acetate inhibits the effects of an excess of male hormone (testosterone) through various mechanisms. It competitively prevents the binding of androgens to their prostatic receptors and blocks the transport of testosterone into the prostate.

No adverse effects on semen quality have been observed.

### **4.3 Pharmacokinetics**

After oral administration with food in dogs, osaterone acetate is rapidly absorbed ( $T_{max}$  about 2 hours) and undergoes a first-pass effect mainly in the liver. After a dose of 0.25 mg/kg/day, the mean maximum concentration ( $C_{max}$ ) in plasma is about 60  $\mu$ g/l.

Osaterone acetate is converted to its main, 15 $\beta$ -hydroxylated metabolite, which is also pharmacologically active. Osaterone acetate and its metabolite are bound to plasma proteins (around 90% and 80% respectively), mainly to albumin. This binding is reversible and not affected by other substances known to specifically bind to albumin.

Osaterone is eliminated within 14 days, mainly in faeces via biliary excretion (60%) and to a lesser extent (25%) in urine. Elimination is slow with a mean half-life ( $T_{1/2}$ ) of about 80 hours. After repeated administration of osaterone acetate at 0.25 mg/kg/day for 7 days, the factor of accumulation is about 3-4 without change in the rates of absorption or elimination. Fifteen days after the last administration, the mean plasma concentration is about 6.5  $\mu$ g/l.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **5.4 Nature and composition of immediate packaging**

Carton box containing one aluminium/aluminium blister with 7 tablets.

**5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/06/068/001  
EU/2/06/068/002  
EU/2/06/068/003  
EU/2/06/068/004

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 11/01/2007

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

**ANNEX II**

**OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX - 1.875 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 1.875 mg tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains 1.875 mg osaterone acetate.

**3. PACKAGE SIZE**

7 tablets.

**4. TARGET SPECIES**

Dogs (male).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/06/068/001

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTER - 1.875 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

1.875 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX - 3.75 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 3.75 mg tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains 3.75 mg osaterone acetate

**3. PACKAGE SIZE**

7 tablets.

**4. TARGET SPECIES**

Dogs (male).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/06/068/002

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTER - 3.75 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

3.75 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX - 7.5 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 7.5 mg tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains 7.5 mg osaterone acetate

**3. PACKAGE SIZE**

7 tablets.

**4. TARGET SPECIES**

Dogs (male).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

**10 THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/06/068/003

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTER - 7.5 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

7.5 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX - 15 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane 15 mg tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains 15 mg osaterone acetate

**3. PACKAGE SIZE**

7 tablets.

**4. TARGET SPECIES**

Dogs (male).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/06/068/004

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTER - 15 mg**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ypozane

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

15 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### **1. Name of the veterinary medicinal product**

YPOZANE 1.875 mg tablets for dogs

YPOZANE 3.75 mg tablets for dogs

YPOZANE 7.5 mg tablets for dogs

YPOZANE 15 mg tablets for dogs

### **2. Composition**

Each tablet contains 1.875 mg, 3.75 mg, 7.5 mg or 15 mg osaterone acetate

Round, white, biconvex tablet of 5.5 mm, 7 mm, 9 mm or 12 mm diameter.

### **3. Target species**

Dogs (male).

### **4. Indications for use**

Treatment of benign prostatic hypertrophy in male dogs.

### **5. Contraindications**

None.

### **6. Special warnings**

#### Special warnings:

In dogs with BPH associated with prostatitis, the product can be administered concurrently with antimicrobials.

#### Special precautions for safe use in the target species:

A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. post-operative) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone.

Use with caution in dogs with a history of liver disease, as safety of use of the product in these dogs has not been thoroughly investigated, and as treatment of some dogs with liver disease has resulted in reversible elevation of ALT and ALP in clinical trials.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease of sexual hormones, reversible after 16 days. There was no clinical effect.

In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions. Therefore, women of child bearing age should avoid contact with, or wear disposable gloves, when administering the product.

#### Overdose:

An overdose study (up to 1.25 mg/kg bodyweight for 10 days, repeated one month later) did not show undesirable effects except for a decrease of cortisol plasma concentration.

### **7. Adverse events**

Dogs (male):

Very common (> 1 animal / 10 animals treated):
Increased appetite <sup>1</sup> Hypocortisolaemia (reduction in plasma cortisol) <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):
Behavioural disorders (e.g., hyperactivity, decreased activity or more social behaviour) <sup>1</sup>
Uncommon (1 to 10 animals / 1,000 animals treated):
Vomiting and/or diarrhoea <sup>1</sup> Polydipsia (increased thirst) <sup>1</sup> , lethargy <sup>1</sup> Polyuria (increased urination) <sup>1</sup> Mammary hyperplasia (mammary enlargement)
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Decreased appetite <sup>1</sup> Galactorrhoea (lactation) <sup>2</sup> Changes in hair coat (e.g., hair loss or hair modification) <sup>1</sup>

<sup>1</sup>Transient.

<sup>2</sup> Associated with mammary hyperplasia.

In clinical trials, treatment with the veterinary medicinal product was not discontinued and all dogs recovered without any specific therapy.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

### **8. Dosage for each species, routes and method of administration**

For oral use.

Administer 0.25 – 0.5 mg osaterone acetate per kilogram bodyweight, once a day, for 7 days as follows:

Dog's weight	Strength of tablet to be administered	Number of tablet per day	Treatment duration
3 to 7.5 kg	1.875 mg tablet	1 tablet	7 days
7.5 to 15 kg	3.75 mg tablet		
15 to 30 kg	7.5 mg tablet		
30 – 60 kg	15 mg tablet		

### **9. Advice on correct administration**

Tablets can be given either directly into the mouth or with food. The onset of clinical response to treatment is usually seen within 2 weeks and persists for at least 5 months after treatment.

Re-evaluation by the veterinarian should take place 5 months after treatment, or earlier if clinical signs recur. A decision to retreat at this or at a later time point should be based on veterinary examination taking into account the risk benefit profile of the medicine.

If clinical response to treatment is considerably shorter than expected, a re-evaluation of the diagnosis is necessary.

The maximum dose should not be exceeded.

### **10. Withdrawal periods**

Not applicable.

### **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister after Exp.

### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/06/068/001-004

Carton box containing one aluminium/aluminium blister with 7 tablets.

**15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available Union Product Database (<https://medicines.health.europa.eu/veterinary>).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC  
1<sup>ère</sup> avenue 2065m LID  
06516 Carros  
France

Local representatives and contact details to report suspected adverse reactions:

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tél/Tel : +32-(0)16 387 260  
phv@virbac.be

**Lietuva**  
OŪ ZOOVETVARU  
Uusaru 5  
76505 Saue/Harjumaa  
Estija  
Tel: + 372 56480207  
pv@zoovet.eu

**Република България**  
САМ БС ЕООД  
Бул. "Д-р Петър Дертлиев" 25, Търговски  
център Лабиринт, ет. 5, офис САМ БС ЕООД  
BG София 1335  
Тел: +359 2 810 0173  
sambs@sambs.bg

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
3001 Leuven  
Belgique / Belgien  
Tél/Tel: +32-(0)16 387 260  
info@virbac.be

**Česká republika**  
VIRBAC Czech Republic, s.r.o.  
Žitavského 496  
CZ 156 00 Praha 5  
Tel: +420 608 836 529

**Magyarország**  
VIRBAC HUNGARY KFT  
Dózsa György út 84. B épület  
HU-1068 Budapest  
Tel.: +36703387177  
akos.csoman@virbac.hu

**Danmark**

VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tlf.: +45 75521244  
virbac@virbac.dk

**Deutschland**

VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: +49 (4531) 805 111

**Eesti**

OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Tel: + 372 56480207  
pv@zoovet.eu

**Ελλάδα**

VIRBAC ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ: +30 210 6219520  
info@virbac.gr

**España**

VIRBAC ESPAÑA, S.A.  
Angel Guimerá 179-181  
ES-08950 - Esplugues de Llobregat  
(Barcelona)  
Tel: + 34 (0) 93 470 79 40

**France**

VIRBAC France  
13<sup>ème</sup> rue LID  
FR-06517 Carros  
Tél : +33 800 73 09 10

**Hrvatska**

CENTRALNA VETERINARSKA AGENCIJA  
d.o.o. (CVA)  
Prve Ravnice 2e,  
HR-10000 Zagreb  
Tel: + 385 91 46 55 112  
cva@cva.hr

**Ireland**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street  
Swords, Co Dublin

**Malta**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
06516 Carros  
Franza  
Tel: +33 (0) 4 92 08 73 00

**Nederland**

VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771 ND-Barneveld  
Tel: +31 (0) 342 427 127  
phv@virbac.nl

**Norge**

VIRBAC Danmark A/S  
Profilvej 1  
6000 Kolding  
Danmark  
Tlf: + 45 75521244  
virbac@virbac.dk

**Österreich**

VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: +43 (0) 1 21 834 260

**Polska**

VIRBAC Sp.z o.o.  
ul. Puławska 314  
PL – 02-819 Warszawa  
Tel.: + 48 22 855 40 46

**Portugal**

VIRBAC DE Portugal LABORATÓRIOS LDA  
Rua do Centro Empresarial  
Edif13-Piso 1- Escrit.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel: 00 351 219 245 020

**România**

ALTIUS SA  
Str. Zăgazului nr. 21-25, Corp A, et 8 si 8A  
Ap. A.8.2, sect 1, București, cod 014261 – RO  
Tel: + 40 21 310 88 80

**Slovenija**

MEDICAL INTERTRADE d.o.o.  
Brodišče 12,  
SI-1236 Trzin  
Tel: + 386 1 2529 113

K67E0A2 - IE  
Tel: +44 (0)-1359 243243

farmakovigilanca@medical-intertrade.si

**Ísland**

VISTOR HF.  
Hörgatún 2,  
IS-210 Garðabær  
Sími: +354 535 7000  
safety@vistor.is

**Slovenská republika**

VIRBAC Czech Republic, s.r.o.  
Žitavského 496  
156 00 Praha 5  
Česká republika  
Tel: +420 608 836 529

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: +39 02 40 92 47 1

**Suomi/Finland**

BIOFARM OY  
Yrittäjätie 20  
FI-03600 Karkkila  
Puh/Tel: +358-9-225 2560  
mikko.koivu@biofarm.fi

**Κύπρος**

ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
14452, Μεταμόρφωση  
Ελλάδα  
Τηλ: +30 2106219520  
info@virbac.gr

**Sverige**

VIRBAC Danmark A/S Filial Sverige  
Box 1027  
SE-171 21 Solna  
Tel: +45 75521244  
virbac@virbac.dk

**Latvija**

OŪ ZOOVETVARU  
Uusaru 5  
76505 Saue/Harjumaa  
Igaunija  
Tel: + 372 56480207  
pv@zoovet.eu

**United Kingdom (Northern Ireland)**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street  
Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**17. Other information**

Benign prostatic hypertrophy (BPH) is a natural consequence of ageing. Over 80% of male dogs above 5 years of age are affected. BPH is a development and enlargement of the prostate due to the male hormone testosterone. This might lead to multiple non-specific clinical signs such as abdominal pain, difficulties in defaecation and urination, blood in urine and locomotive disorders.